Instrument Inactif

Communiqués Kadmon Holdings, Inc.

Actions

KDMN

US48283N1063

Produits pharmaceutiques

Communiqués

09/11/21	Sanofi completes acquisition of Kadmon - Form 8-K	PU
09/11/21	KADMON HOLDINGS, INC. : Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendme (form 8-K)	AQ
05/11/21	KADMON HOLDINGS, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)	AQ
04/11/21	Kadmon Provides Business Update and Reports Third Quarter 2021 Financial Results	PU
04/11/21	KADMON HOLDINGS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	AQ
04/11/21	Kadmon Provides Business Update and Reports Third Quarter 2021 Financial Results - Form 8-K	PU
28/10/21	KADMON HOLDINGS, INC. : Other Events (form 8-K)	AQ
21/10/21	KADMON HOLDINGS, INC. : Other Events (form 8-K)	AQ
01/10/21	Kadmon : Announces Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer's 36th Annual Meeting	PU
11/09/21	KADMON HOLDINGS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kadmon Holdings, Inc. - KDMN	BU
08/09/21	Kadmon : Sanofi to acquire Kadmon to further strengthen growth of transplant business (Form 8-K)	PU
08/09/21	KADMON HOLDINGS, INC. : Entry into a Material Definitive Agreement, Change in Directors or Principal Officers, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
19/08/21	Kadmon : Announces U.S. Availability of REZUROCK(TM) (belumosudil) for the Treatment of Patients with Chronic Graft-Versus-Host Disease (cGVHD)	PU
05/08/21	KADMON : Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	AQ
04/08/21	Kadmon : Announces REZUROCK(TM) (belumosudil) Added to National Comprehensive Cancer Network(R) Clinical Practice Guidelines in Oncology for Hematopoietic Cell Transplantation	PU
27/07/21	Kadmon : Corporate Presentation	PU
19/07/21	Kadmon : REZUROCK is approved for the treatment of adult and pediatric patients 12 years and older with cGVHD after failure of at least two prior lines of systemic therapy (Form 8-K)	PU
19/07/21	KADMON HOLDINGS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)	AQ
19/07/21	Kadmon : Announces Pivotal Trial Data Published in the Journal Blood for REZUROCK(TM) (Belumosudil) in Chronic Graft-Versus-Host Disease (cGVHD)	PU
16/07/21	Kadmon : Kadmon Holdings, Inc.	AQ
16/07/21	Kadmon : U.S. FDA Grants Full Approval of REZUROCK(TM) (belumosudil) for the Treatment of Patients with Chronic Graft-Versus-Host Disease (cGVHD)	PU
30/06/21	Kadmon : KD033 Presentation	PU
30/06/21	Kadmon : Corporate Presentation	PU
28/06/21	Kadmon : Corporate Presentation	PU
15/06/21	ROCKstar: Belumosudil in cGVHD – EHA 2021 Slides	PU